Chemomab Therapeutics Ltd.

Recent Developments

In August 2025, we announced our plan to change the ratio of our ADSs to our ordinary shares (the “ADS Ratio”), from the current ADS Ratio of one ADS to 20 ordinary shares to a new ADS Ratio of one ADS to 80 ordinary shares, effective on August 26, 2025. We will continue to be traded on the Nasdaq Capital Market under the ticker “CMMB”, with an updated CUSIP Number of 16385C203. This ratio adjustment will essentially serve as a one-for-four reverse ADS split for ADS holders, requiring no action on their part. The Bank of New York Mellon, serving as the depositary bank for our ADS program, will arrange for the exchange of every four existing ADSs held for one new ADS on the effective date. There will be no issuance of new ADSs in connection with the adjustment. Any fractional shares resulting from the adjustment will be aggregated and the depositary bank will attempt to sell them and distribute the net proceeds to the respective ADS holders.

In July 2025, we entered into a Sales Agreement with LifeSci Capital, LLC (“LifeSci”) pursuant to which we may offer and sell, from time to time, ADSs through LifeSci in an At-the-Market offering for an aggregate offering price of up to $7,258,687.

In June 2025, we reported that two new patents covering the use of nebokitug for the treatment of liver diseases including primary sclerosing cholangitis were issued in China and Russia, providing coverage up to 2041. These new patents further expand the protections provided by nebokitug’s composition of matter and methods and use patents issued in the U.S., Europe, Japan and additional key territories

In June 2025, we obtained confirmation from the FDA on two development milestones for the nebokitug Phase 3 program. These included agreement with the FDA on the Chemistry, Manufacturing, and Controls (CMC) strategy proposed by us and our contract manufacturing partner and agreement that additional animal toxicology testing required by the FDA may be conducted in parallel with the nebokitug Phase 3 clinical trial and submitted as part of the planned Biologics Licensing Application (BLA). This represents a favorable outcome for us and supports the timely advancement of the program.

In May and June, 2025, we reported that Phase 2 clinical data on nebokitug for the treatment of PSC was presented at several major scientific conferences including DDW25--Digestive Disease Week 2025®; EASL 2025--the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25-the British Society of Gastroenterology’s annual meeting. The DDW25 presentation was an oral presentation in the Liver & Biliary Distinguished Abstract Plenary session and Professor Douglas Thorburn’s talk on the nebokitug SPRING trial results was awarded the prize for the Best Oral Presentation in its respective category at BSG LIVE'25.

In April 2025 we announced that David M. Weiner, MD, had rejoined Chemomab as Interim Chief Medical Officer, replacing Chief Medical Officer Matt Frankel, MD, who resigned to pursue other opportunities. Dr. Weiner spearheaded key revisions to the Phase 2 SPRING trial protocol and brings extensive biotechnology and pharmaceutical industry R&D, drug development and strategic experience to Chemomab. The Company also announced that Jack Lawler, who oversaw the conduct of our successful Phase 2 SPRING trial, was named Chief Development Officer.